Exempt Chemical Preparations Under the Controlled Substances Act, 26944-26951 [2017-12110]
Download as PDF
asabaliauskas on DSKBBXCHB2PROD with NOTICES
26944
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
a limited exclusion order prohibiting
importation of infringing lithium metal
oxide cathode materials based upon
settlement.
FOR FURTHER INFORMATION CONTACT:
Panyin A. Hughes, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW.,
Washington, DC 20436, telephone 202–
205–3042. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on 202–205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted the underlying
investigation on March 30, 2015, based
on a complaint filed by BASF
Corporation of Florham Park, New
Jersey (‘‘BASF’’) and UChicago Argonne
LLC of Lemont, IL (‘‘Argonne’’)
(collectively, ‘‘Complainants’’). 80 FR
16696 (Mar. 30, 2015). The complaint
alleged violations of section 337 of the
Tariff Act of 1930, as amended (19
U.S.C. 1337), in the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain lithium
metal oxide cathode materials, lithiumion batteries for power tool products
containing same, and power tool
products with lithium-ion batteries
containing same by reason of
infringement of one or more of claims
1–4, 7, 13, and 14 of U.S. Patent No.
6,677,082 (‘‘the ’082 patent’’) and claims
1–4, 8, 9, and 17 of U.S. Patent No.
6,680,143 (‘‘the ’143 patent’’). Id. The
notice of investigation named the
following respondents: Umicore N.V. of
Brussels, Belgium; Umicore USA Inc. of
Raleigh, North Carolina (collectively,
‘‘Umicore’’); Makita Corporation of
Anjo, Japan; Makita Corporation of
America of Buford, Georgia; and Makita
U.S.A. Inc. of La Mirada, California
(collectively, ‘‘Makita’’). Id. The Office
of Unfair Import Investigations was a
party to the investigation.
On November 5, 2015, the ALJ
granted a joint motion by Complainants
and Makita to terminate the
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
investigation as to Makita based upon
settlement. See Order No. 32 (Nov. 5,
2015). The Commission determined not
to review this order. See Notice of NonReview (Nov. 23, 2015).
On February 29, 2016, the ALJ issued
his final initial determination (‘‘ID’’),
finding a violation of section 337 by
Umicore in connection with claims 1–
4, 7, 13, and 14 of the ’082 patent and
claims 1–4, 8, 9, and 17 of the ’143
patent. On May 11, 2016, the
Commission determined to review the
final ID in part. 81 FR 30548–50 (May
17, 2016). The Commission also granted
Umicore’s request for a Commission
hearing. Id. On November 17, 2016, the
Commission held a hearing on
contributory infringement, laches, and
the public interest. On review, the
Commission determined to affirm the
ALJ’s finding of violation of section 337
with respect to the claims identified
above. 81 FR 93960–62 (Dec. 22, 2016).
Having found a violation of section
337, the Commission determined that
the appropriate form of relief was: A
limited exclusion order prohibiting the
unlicensed entry of lithium metal oxide
cathode materials that infringe one or
more of claims 1–4, 7, 13, and 14 of the
’082 patent, or claims 1–4, 8, 9, and 17
of the ’143 patent that are manufactured
by, or on behalf of, or imported by or on
behalf of Umicore N.V. and Umicore
USA Inc. or any of their affiliated
companies, parents, subsidiaries, agents,
or other related business entities, or
their successors or assigns.
On May 5, 2017, BASF, Argonne, and
Umicore filed a joint petition under 19
U.S.C. 1337(k) and Commission Rule
210.76(a) (19 CFR 210.76(a)) to rescind
the limited exclusion order based upon
settlement. The parties filed both
confidential and public versions of the
settlement agreements. On May 9, 2017,
the Commission investigative attorney
filed a response in support of the
motion.
The Commission has determined to
grant the petition. The limited exclusion
order issued in this investigation is
hereby rescinded.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR 210).
By order of the Commission.
Issued: June 6, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–12035 Filed 6–9–17; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–372]
Exempt Chemical Preparations Under
the Controlled Substances Act
Drug Enforcement
Administration, Department of Justice.
ACTION: Order with opportunity for
comment.
AGENCY:
The applications for exempt
chemical preparations received by the
Drug Enforcement Administration
(DEA) between April 1, 2016, and
December 31, 2016, as listed below,
were accepted for filing and have been
approved or denied as indicated.
DATES: Interested persons may file
written comments on this order in
accordance with 21 CFR 1308.23(e).
Electronic comments must be
submitted, and written comments must
be postmarked, on or before August 11,
2017. Commenters should be aware that
the electronic Federal Docket
Management System will not accept
comments after 11:59 p.m. Eastern Time
on the last day of the comment period.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–372’’ on all correspondence,
including any attachments.
• Electronic comments: The Drug
Enforcement Administration (DEA)
encourages that all comments be
submitted through the Federal
eRulemaking Portal, which provides the
ability to type short comments directly
into the comment field on the Web page
or to attach a file for lengthier
comments. Please go to https://
www.regulations.gov and follow the
online instructions at that site for
submitting comments. Upon completion
of your submission you will receive a
Comment Tracking Number for your
comment. Please be aware that
submitted comments are not
instantaneously available for public
view on Regulations.gov. If you have
received a comment tracking number,
your comment has been successfully
submitted and there is no need to
resubmit the same comment.
• Paper comments: Paper comments
that duplicate the electronic submission
are not necessary and are discouraged.
Should you wish to mail a comment in
lieu of an electronic comment, it should
be sent via regular or express mail to:
Drug Enforcement Administration,
Attention: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT:
Michael J. Lewis, Diversion Control
SUMMARY:
E:\FR\FM\12JNN1.SGM
12JNN1
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments
received are considered part of the
public record and made available for
public inspection online at https://
www.regulations.gov and in the DEA’s
public docket. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want posted online or made
available in the public docket in the first
paragraph of your comment and identify
what information you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment.
Comments containing personal
identifying information and confidential
business information identified as
directed above will generally be made
publicly available in redacted form. If a
comment has so much confidential
business information that it cannot be
effectively redacted, all or part of that
comment may not be made publicly
available. Comments posted to https://
www.regulations.gov may include any
personal identifying information (such
as name, address, and phone number)
included in the text of your electronic
submission that is not identified as
directed above as confidential.
An electronic copy of this document
is available at https://
www.regulations.gov for easy reference.
Legal Authority
The Drug Enforcement
Administration (DEA) implements and
enforces titles II and III of the
Comprehensive Drug Abuse Prevention
and Control Act of 1970, as amended.
Titles II and II are referred to as the
‘‘Controlled Substances Act’’ and the
‘‘Controlled Substances Import and
Export Act,’’ or the ‘‘CSA’’ for the
purpose of this action. 21 U.S.C. 801–
971. The DEA publishes the
implementing regulations for these
statutes in title 21 of the Code of Federal
Regulations (CFR), chapter II.
The CSA and its implementing
regulations are designed to prevent,
detect, and eliminate the diversion of
controlled substances and listed
chemicals into the illicit market while
ensuring an adequate supply is available
for the legitimate medical, scientific,
research, and industrial needs of the
United States. Controlled substances
have the potential for abuse and
dependence and are controlled to
protect the public health and safety.
Section 201 of the CSA (21 U.S.C.
811) authorizes the Attorney General, by
regulation, to exempt from certain
provisions of the CSA certain
compounds, mixtures, or preparations
containing a controlled substance, if he
finds that such compounds, mixtures, or
preparations meet the requirements
detailed in 21 U.S.C. 811(g)(3)(B).1 The
DEA regulations at 21 CFR 1308.23 and
1308.24 further detail the criteria by
which the DEA Assistant Administrator
may exempt a chemical preparation or
mixture from certain provisions of the
CSA. The Assistant Administrator may,
pursuant to 21 CFR 1308.23(f), modify
or revoke the criteria by which
exemptions are granted and modify the
scope of exemptions at any time.
26945
Exempt Chemical Preparation
Applications Submitted Between April
1, 2016, and December 31, 2016
The Assistant Administrator received
applications between April 1, 2016, and
December 31, 2016, requesting exempt
chemical preparation status detailed in
21 CFR 1308.23. Pursuant to the criteria
stated in 21 U.S.C. 811(g)(3)(B) and in
21 CFR 1308.23, the Assistant
Administrator has found that each of the
compounds, mixtures, and preparations
described in Chart I below is intended
for laboratory, industrial, educational,
or special research purposes and not for
general administration to a human being
or animal and either: (1) Contains no
narcotic controlled substance and is
packaged in such a form or
concentration that the packaged
quantity does not present any
significant potential for abuse; or (2)
contains either a narcotic or nonnarcotic controlled substance and one or
more adulterating or denaturing agents
in such a manner, combination,
quantity, proportion, or concentration
that the preparation or mixture does not
present any potential for abuse; if the
preparation or mixture contains a
narcotic controlled substance, it must be
formulated in such a manner that it
incorporates methods of denaturing or
other means so that the preparation or
mixture is not liable to be abused or
have ill effects if abused, and so that the
narcotic substance cannot in practice be
removed.
Accordingly, pursuant to 21 U.S.C.
811(g)(3)(B), 21 CFR 1308.23, and 21
CFR 1308.24, the Assistant
Administrator has determined that each
of the chemical preparations or mixtures
generally described in Chart I below and
specifically described in the application
materials received by the DEA, is
exempt, to the extent described in 21
CFR 1308.24, from application of
sections 302, 303, 305, 306, 307, 308,
309, 1002, 1003, and 1004 (21 U.S.C.
822–823, 825–829, and 952–954) of the
CSA, and 21 CFR 1301.74, as of the date
that was provided in the approval letters
to the individual requesters.
CHART I
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Supplier
Product name
Form
Aalto Scientific, Ltd .....................
Aalto Scientific, Ltd .....................
Aalto Scientific, Ltd .....................
Absolute Standards, Inc ..............
Absolute Standards, Inc ..............
Absolute Standards, Inc ..............
Endocrine Program .........................................................................
Endocrinology ..................................................................................
Linearity FD Testosterone, Siemens Centaur .................................
ISO G34 Calibrator Spike High .......................................................
ISO G34 Calibrator Spike Low ........................................................
ISO G34 Calibrator Spike Solution .................................................
Amber vial: 5 mL .............
Amber vial: 5 mL .............
Kit: 5 vials; 3 mL each .....
Glass ampoule: 1 mL ......
Glass ampoule: 1 mL ......
Glass ampoule: 1 mL ......
1 This authority has been delegated from the
Attorney General to the Administrator of the DEA
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
by 28 CFR 0.100, and subsequently redelegated to
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Application
date
8/23/2016
8/23/2016
12/7/2016
8/3/2016
8/3/2016
8/3/2016
the Deputy Assistant Administrator pursuant to
Section 7 of 28 CFR 0.104, Appendix to Subpart R.
E:\FR\FM\12JNN1.SGM
12JNN1
26946
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
CHART I—Continued
Application
date
Supplier
Product name
Form
Absolute Standards, Inc ..............
Accriva Diagnostics, Inc ..............
ISO G34 Internal Standard .............................................................
Hemochron PT ................................................................................
Arbor Assays ...............................
Arbor Assays ...............................
Arbor Assays ...............................
Arbor Assays ...............................
Arbor Assays ...............................
Arbor Assays ...............................
Biochemical Diagnostics, Inc ......
Biochemical Diagnostics, Inc ......
Biochemical Diagnostics, Inc ......
Biochemical Diagnostics, Inc ......
Biochemical Diagnostics, Inc ......
Biochemical Diagnostics, Inc ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Testosterone 5-pack Enzyme Immunoassay Kit (K032–H5) ..........
Testosterone Enzyme Immunoassay Kit (ISWE001) ......................
Testosterone Enzyme Immunoassay Kit (K032–H1) ......................
Testosterone Standard (1,000 ng/mL) ............................................
Testosterone Standard (200,000 pg/mL) ........................................
Testosterone Standard (200,000 pg/mL) ........................................
Detectabuse Custom Liquid Control Urine, MC252 ........................
Detectabuse Custom Liquid Control Urine, MC253 ........................
Detectabuse Custom Liquid Control Urine, MC254 ........................
Detectabuse Custom Liquid Control Urine, MC255 ........................
Detectabuse Custom Liquid Control Urine, MC256 ........................
Detectabuse Custom Liquid Control Urine, MC257 ........................
11-Keto Testosterone CRM; 1 mg/mL in Acetonitrile .....................
AB-CHMINACA (CRM); 1 mg/mL in Acetonitrile ............................
AB-CHMINACA (CRM); 1 mg/mL in Methanol ...............................
AB-CHMINACA (CRM); 100 μg/mL in Acetonitrile .........................
AB-CHMINACA (CRM); 100 μg/mL in Methanol ............................
AB-PINACA CRM; 1 mg/mL in Methanol .......................................
Acetyl Fentanyl CRM; 1 mg/mL in Methanol ..................................
Acetyl Fentanyl CRM; 100 μg/mL in Methanol ...............................
Cocaine CRM; 1 mg/mL in Acetonitrile ...........................................
Cocaine/Heroin/Methamphetamine Mixture CRM; 1 mg/mL each
in Acetonitrile.
Cocaine/Heroin/Methamphetamine Mixture CRM; 100 μg/mL
each in Acetonitrile.
Cocaine/Heroin/Methamphetamine Mixture CRM; 250 μg/mL
each in Acetonitrile.
Cocaine/Heroin/Methamphetamine Mixture CRM; 500 μg/mL
each in Acetonitrile.
GC-MS Drug Standard Mixture 1 in Acetonitrile .............................
Phytocannabinoid Mixture 1; 1 mg/mL in Acetonitrile ....................
Tapentadol (hydrochloride) CRM; 1 mg/mL in Acetonitrile .............
Tapentadol (hydrochloride) CRM; 1 mg/mL in Methanol ................
Tapentadol (hydrochloride) CRM; 100 μg/mL in Acetonitrile ..........
Tapentadol (hydrochloride) CRM; 100 μg/mL in Methanol .............
THJ2201 (CRM); 1 mg/mL in Acetonitrile .......................................
THJ2201 (CRM); 1 mg/mL in Methanol ..........................................
THJ2201 (CRM); 100 μg/mL in Acetonitrile ....................................
THJ2201 (CRM); 100 μg/mL in Methanol .......................................
ToxBox THC/THC Metabolite Plate ................................................
(±)-11-Hydroxy-delta9–THC glucuronide (0.01 mg/mL) ..................
(±)-Cannabicyclol (1.0 mg/mL) ........................................................
(±)-cis-3-Methylfentanyl HCl (0.05 mg/mL) .....................................
(±)-cis-3-Methylfentanyl HCl (0.1 mg/mL) .......................................
5alpha-Dihydrotestosterone-D3 [16, 16, 17–D3]; 10 μg/mL ...........
6beta-Naltrexol (1 mg/mL) ..............................................................
AH-7921 HCl (1 mg/mL) .................................................................
AH-7921-D3 HCl (0.1 mg/mL) .........................................................
Brivaracetam-D3 (0.1 mg/mL) .........................................................
Butyryl fentanyl (0.05 mg/mL) .........................................................
Butyryl fentanyl (0.1 mg/mL) ...........................................................
Cannabichromenic acid (CBCA) (1.0 mg/mL) ................................
Cannabicyclolic acid (CBLA) (1.0 mg/mL) ......................................
Carfentanil (0.1 mg/mL) ..................................................................
Carfentanil oxalate (0.1 mg/mL) ......................................................
Carfentanil-D5 oxalate (0.1 mg/mL) ................................................
Clorazepate dipotassium (1 mg/mL) ...............................................
Dihydrotestosterone Calibrator Level 1 (20 pg/mL) ........................
Dihydrotestosterone Calibrator Level 2 (50 pg/mL) ........................
Dihydrotestosterone Calibrator Level 3 (100 pg/mL) ......................
Dihydrotestosterone Calibrator Level 4 (500 pg/mL) ......................
Dihydrotestosterone Calibrator Level 5 (1000 pg/mL) ....................
Dihydrotestosterone Calibrator Level 6 (2500 pg/mL) ....................
Dihydrotestosterone Calibrator Level 7 (10 ng/mL) ........................
Diphenoxylate HCl (1 mg/mL) .........................................................
Furanyl fentanyl (0.1 mg/mL) ..........................................................
Norhydromorphone-D3 HCl (0.1 mg/mL) ........................................
Noroxymorphone-D3 HCl (0.1 mg/mL) ...........................................
Glass ampoule: 1 mL ......
Box: 45 cuvettes; 7.5μL
each.
Kit: 400 μL vial .................
Kit: 1 mL vial ....................
Kit: 90 μL vial ...................
Plastic vial: 1 mL .............
Plastic vial: 90 μL ............
Plastic vial: 400 μL ..........
Glass vial: 1 mL–200 mL
Glass vials: 1 ml–200 mL
Glass vial: 1 mL–200 mL
Glass vial: 1 mL–200 mL
Glass vials: 1 ml–200 mL
Glass vials: 1 ml–200 mL
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
10/18/2016
10/18/2016
10/18/2016
10/18/2016
10/18/2016
10/18/2016
7/29/2016
9/30/2016
7/29/2016
7/29/2016
12/19/2016
12/19/2016
6/28/2016
8/26/2016
8/26/2016
8/26/2016
8/26/2016
6/28/2016
6/28/2016
6/28/2016
6/28/2016
8/26/2016
Glass ampule: 1 mL ........
8/26/2016
Glass ampule: 1 mL ........
8/26/2016
Glass ampule: 1 mL ........
8/26/2016
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
48-well plate .....................
Glass ampule: 1 mL ........
Glass ampule: 1.0 mL .....
Glass ampule: 1 mL ........
Glass ampule: 0.5 mL .....
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 0.5 mL .....
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 0.5 mL .....
Glass ampule: 0.5 mL .....
Glass ampule: 0.5 mL .....
Glass ampule: 1 mL ........
Cryovial: 1 mL ..................
Cryovial: 1 mL ..................
Cryovial: 1 mL ..................
Cryovial: 1 mL ..................
Cryovial: 1 mL ..................
Cryovial: 1 mL ..................
Cryovial: 1 mL ..................
Glass ampule: 1 mL ........
Glass ampule: 0.5 mL .....
Glass ampule: 1.0 mL .....
Glass ampule: 1.0 mL .....
6/28/2016
6/28/2016
8/26/2016
8/26/2016
8/26/2016
8/26/2016
8/26/2016
8/26/2016
8/26/2016
8/26/2016
6/28/2016
11/11/2016
7/18/2016
6/21/2016
7/18/2016
9/28/2016
5/6/2016
5/20/2016
5/20/2016
11/30/2016
6/21/2016
7/18/2016
11/30/2016
11/30/2016
9/28/2016
11/30/2016
11/30/2016
5/6/2016
8/12/2016
8/12/2016
8/12/2016
8/12/2016
8/12/2016
8/12/2016
8/12/2016
5/20/2016
11/30/2016
7/18/2016
7/18/2016
Cayman Chemical Company ......
Cayman Chemical Company ......
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cayman Chemical Company ......
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\12JNN1.SGM
12JNN1
8/3/2016
5/17/2016
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
26947
CHART I—Continued
Application
date
Supplier
Product name
Form
Cerilliant Corporation ..................
Cerilliant Corporation ..................
Cerilliant Corporation ..................
IDEXX Laboratories ....................
Pholcodine (1 mg/mL) .....................................................................
Tapentadol-D3 HCl (1 mg/mL) ........................................................
U-47700 (1.0 mg/mL) ......................................................................
Coag Dx PT .....................................................................................
5/6/2016
11/11/2016
11/30/2016
10/21/2016
IDEXX Laboratories ....................
Immunalysis Corporation ............
Coag Dx PT Cartridge .....................................................................
cTHC Urine Calibrator 1 (20 ng/mL) ...............................................
Immunalysis Corporation ............
cTHC Urine Calibrator 2 (50 ng/mL) ...............................................
Immunalysis Corporation ............
cTHC Urine Calibrator 3 (100 ng/mL) .............................................
Immunalysis Corporation ............
cTHC Urine Calibrator 4 (200 ng/mL) .............................................
Immunalysis Corporation ............
cTHC Urine Control HIGH (62.5 ng/mL) .........................................
Immunalysis Corporation ............
cTHC Urine Control LOW (37.5 ng/mL) ..........................................
Immunalysis
Immunalysis
Immunalysis
Immunalysis
Immunalysis
Immunalysis
............
............
............
............
............
............
Fentanyl Urine Calibrator 1 (1 ng/mL) ............................................
Fentanyl Urine Calibrator 2 (2 ng/mL) ............................................
Fentanyl Urine Calibrator 3 (4 ng/mL) ............................................
Fentanyl Urine Control HIGH (1.5 ng/mL) ......................................
Fentanyl Urine Control LOW (0.5 ng/mL) .......................................
MDC Calibrator 1 ............................................................................
Immunalysis Corporation ............
MDC Calibrator 2 ............................................................................
Immunalysis Corporation ............
MDC Calibrator 3 ............................................................................
Immunalysis Corporation ............
MDC Calibrator 4 ............................................................................
Immunalysis Corporation ............
MDC Control HIGH Set 1 ................................................................
Immunalysis Corporation ............
MDC Control HIGH Set 1 ................................................................
Immunalysis Corporation ............
MDC Control LOW Set 1 ................................................................
Immunalysis Corporation ............
MDC Control LOW Set 2 ................................................................
Immunalysis Corporation ............
Opiates Urine Calibrator 2000 1 (1000 ng/mL) ..............................
Immunalysis Corporation ............
Opiates Urine Calibrator 2000 2 (2000 ng/mL) ..............................
Immunalysis Corporation ............
Opiates Urine Calibrator 2000 3 (4000 ng/mL) ..............................
Immunalysis Corporation ............
Opiates Urine Calibrator 2000 4 (6000 ng/mL) ..............................
Immunalysis Corporation ............
Oxazepam Urine Control HIGH (125 ng/mL) ..................................
Immunalysis Corporation ............
Oxazepam Urine Control LOW (75 ng/mL) ....................................
Instrumentation Laboratory .........
Gem Test PT ...................................................................................
IsoSciences, LLC ........................
IsoSciences, LLC ........................
Codeine-[13C4, 15N], 1000 μg/mL in methanol .............................
Codeine-6b-Glucuronide-[13C10, 15N], 1000 μg/mL in methanol:water (2:8).
Morphine-[13C4, 15N], 1000 μg/mL in methanol ............................
Morphine-6b-Glucuronide-[13C10, 15N], 1000 μg/mL in methanol:water (2:8).
Testosterone-[2H8], 100 μg/mL in methanol ..................................
Testosterone-[2H8], 1000 μg/mL in methanol ................................
Hemochron Jr ..................................................................................
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Box: 10 cartridges; 7.5μL
each.
Cartridges: 7.5μL each ....
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL ........
Dropper bottle: 5 mL ........
Dropper bottle: 5 mL ........
Dropper bottle: 5 mL ........
Dropper bottle: 5 mL ........
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 15 mL, 25
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Dropper bottle: 5 mL, 15
mL.
Box: 45 cuvettes; 7.5μL
each.
Amber ampule: 1 mL .......
Amber ampule: 1 mL .......
Amber ampule: 1 mL .......
Amber ampule: 1 mL .......
10/20/2016
10/20/2016
Amber Ampule: 1 mL .......
Amber Ampule: 1 mL .......
Box: 45 cuvettes; 7.5μL
each.
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
8/10/2016
8/10/2016
7/1/2016
Corporation
Corporation
Corporation
Corporation
Corporation
Corporation
asabaliauskas on DSKBBXCHB2PROD with NOTICES
IsoSciences, LLC ........................
IsoSciences, LLC ........................
IsoSciences, LLC ........................
IsoSciences, LLC ........................
ITC ...............................................
Lipomed
Lipomed
Lipomed
Lipomed
Lipomed
Lipomed
Lipomed
Inc
Inc
Inc
Inc
Inc
Inc
Inc
VerDate Sep<11>2014
.................................
.................................
.................................
.................................
.................................
.................................
.................................
17:28 Jun 09, 2017
25B-NB2OMe (1 mg/mL methanol) ................................................
25C-NB2OMe (1 mg/mL methanol) ................................................
25I-NB2OMe (1 mg/mL methanol) ..................................................
25I-NB2OMe-D9 (0.1 mg/mL methanol) .........................................
25I-NB2OMe-D9 (1 mg/mL methanol) ............................................
3,4-Methylendioxypyrovalerone (1 mg/mL methanol) .....................
3,4-Methylenedioxy-a-pyrrolidinopropiophenone (1 mg/mL methanol).
Jkt 241001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
E:\FR\FM\12JNN1.SGM
12JNN1
10/21/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
5/27/2016
10/6/2016
10/20/2016
10/20/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
26948
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
CHART I—Continued
Application
date
Product name
Form
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Lipomed Inc .................................
Microgenics Corporation .............
3-Desmethylprodine (1 mg/mL acetonitrile) ....................................
4-Ethylmethcathinone (1 mg/mL methanol) ....................................
4-Methylethcathinone (1 mg/mL methanol) ....................................
4-Methylmethcathinone (1 mg/mL methanol) .................................
4-Methylmethcathinone-D3 (0.1 mg/mL methanol) .........................
4-Methylmethcathinone-D3 (1 mg/mL methanol) ............................
Benzodiazepines mixture (.001 mg free base/ml acetonitrile) ........
Benzodiazepines mixture 5 (1 mg free base/mL acetonitrile) ........
Bufotenine.oxalate.monohydrate (1 mg/mL methanol) ...................
Butabarbital (1 mg/mL methanol) ....................................................
Butalbital (1 mg/mL methanol) ........................................................
Butalbital-D5 (1 mg/mL methanol) ..................................................
Butylone (1 mg/mL methanol) .........................................................
Cannabidiol-D3 (0.1 mg/mL methanol) ...........................................
Cannabidiol-D3 (1 mg/mL methanol) ..............................................
Cannabinol-D3 (0.1 mg/mL methanol) ............................................
Cannabinol-D3 (1 mg/mL methanol) ...............................................
Carisoprodol (1 mg/mL methanol) ..................................................
Clotiazepam (1 mg/mL methanol) ...................................................
Cocaethylene-D3 (1 mg/mL acetonitrile) ........................................
Cocaine mixture 2 (1 mg/mL methanol) .........................................
Desomorphine (1 mg/mL acetonitrile) .............................................
Ethylone (1 mg/mL methanol) .........................................................
JWH-018 (0.1 mg/mL methanol) .....................................................
JWH-018 (1 mg/mL methanol) ........................................................
JWH-018–D11 metabolite (0.1 mg/mL methanol) ..........................
JWH-018–D11 metabolite (1 mg/mL methanol) .............................
JWH-019 (0.1 mg/mL methanol) .....................................................
JWH-019 (1 mg/mL methanol) ........................................................
JWH-081 (0.1 mg/mL methanol) .....................................................
JWH-081 (1 mg/mL methanol) ........................................................
JWH-122 (0.1 mg/mL methanol) .....................................................
JWH-122 (1 mg/mL methanol) ........................................................
JWH-200 (0.1 mg/mL methanol) .....................................................
JWH-200 (1 mg/mL methanol) ........................................................
L-Methamphetamine (1 mg/mL methanol) ......................................
Loprazolam (1 mg/mL methanol) ....................................................
Mazindol (1 mg/mL Dimethylformamide) ........................................
Meprobamate (1 mg/mL methanol) .................................................
Methandienone (1 mg/mL methanol) ..............................................
Methylone (1 mg/mL methanol) ......................................................
Methylone-D3 (0.1 mg/mL methanol) .............................................
Methylone-D3 (1 mg/mL methanol) ................................................
N,N-Dimethylamphetamine (1 mg/mL methanol) ............................
Naphyrone (1 mg/mL methanol) .....................................................
Nimetazepam (1 mg/mL methanol) .................................................
Norbuprenorphine (1 mg/mL methanol) ..........................................
Normeperidine (1 mg/mL methanol) ...............................................
Pentedrone (1 mg/mL methanol) ....................................................
Pentylone (1 mg/mL methanol) .......................................................
Phenobarbital-D5 (side chain) (0.1 mg/mL methanol) ....................
Phenobarbital-D5 (side chain) (1 mg/mL methanol) .......................
Pregabalin (1 mg/mL methanol) ......................................................
Propoxyphen-D5 (0.1 mg/mL methanol) .........................................
Propoxyphen-D5 (1 mg/mL methanol) ............................................
Pyrovalerone (1 mg/mL methanol) ..................................................
a-Pyrrolidinopropiophenone (1 mg/mL methanol) ..........................
a-Pyrrolidinovalerophenone (1 mg/mL methanol) ...........................
Cascadion SM Total Testosterone Internal Standard .....................
Cedia Buprenorphine OFT Control Set (Low and High) Catalog
Number: 10022377.
Cedia Buprenorphine OFT Cutoff Calibrator Catalog Number:
10022376.
Cedia Multi-Drug OFT Cutoff Calibrator Set B Catalog Number:
10022355.
Cedia Multi-Drug OFT Cutoff Control Set B (Low and High) Catalog Number: 10022356.
Intercept i2he Multi-Drug Oral Fluid Cutoff Calibrator Set B Catalog Number: 1001–0419.
Intercept i2he Multi-Drug Oral Fluid Cutoff Control Set B (Low
and High) Catalog Number: 1001–0420.
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Glass ampule: 1 mL ........
Box: 8 bottles, 29 mL
each.
Vial: 10 mL; Box: 2 vials ..
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
10/28/2016
12/16/2016
Microgenics Corporation .............
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Supplier
Vial: 5 mL; Box: 1 vial .....
11/15/2016
Vial: 10 mL; Box: 1 vial ...
10/20/2016
Vial: 15 mL; Box: 2 vials ..
10/20/2016
Vial: 10 mL; Box: 1 vial ...
10/19/2016
Vial: 15 mL; Box: 2 vials ..
10/19/2016
Microgenics Corporation .............
Microgenics Corporation .............
Microgenics Corporation .............
Microgenics Corporation .............
Microgenics Corporation .............
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
E:\FR\FM\12JNN1.SGM
12JNN1
11/15/2016
26949
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
CHART I—Continued
Application
date
Supplier
Product name
Form
Microgenics Corporation .............
Vial: 5 mL Box: 1 vial ......
8/30/2016
Vial: 5 mL Box: 1 vial ......
8/30/2016
Vial: 5 mL Box: 1 vial ......
8/30/2016
Vial: 5 mL Box: 1 vial ......
8/30/2016
Vial: 5 mL Box: 4 vials .....
8/30/2016
Healthcare Diagnostics,
Thermo Scientific CEDIA Buprenorphine II Calibrator 10 ng/mL
Catalog Number: 10020799.
Thermo Scientific CEDIA Buprenorphine II Calibrator 100 ng/mL
Catalog Number: 10020802.
Thermo Scientific CEDIA Buprenorphine II Calibrator 20 ng/mL
Catalog Number: 10020800.
Thermo Scientific CEDIA Buprenorphine II Calibrator 50 ng/mL
Catalog Number: 10020801.
Thermo Scientific CEDIA Buprenorphine II Controls (Low and
High) Catalog Number: 10020804.
BK Emit II Plus Oxycodone Negative Control 100 .........................
Bulk Container: 1 L–50 L
8/23/2016
Healthcare Diagnostics,
Emit II Plus Oxycodone Negative Control 100 ...............................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Oxycodone Negative Control 300 ...............................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Oxycodone Positive Control 100 .................................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Oxycodone Positive Control 300 .................................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Specialty Multi Drug Calibrator/Control Level 1 ..........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Specialty Multi Drug Calibrator/Control Level 2 ..........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Specialty Multi Drug Calibrator/Control Level 3 ..........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Emit II Plus Specialty Multi Drug Calibrator/Control Level 4 ..........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Oxycodone Negative Control 100 .........................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Oxycodone Negative Control 300 .........................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Oxycodone Positive Control 100 ...........................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Oxycodone Positive Control 300 ...........................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 1 ....
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 2 ....
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 3 ....
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 4 ....
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Oxycodone Negative Control 100 ..............................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Oxycodone Negative Control 300 ..............................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Oxycodone Positive Control 100 ................................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Oxycodone Positive Control 300 ................................
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Specialty Multi Drug Calibrator/Control LVL 1 ...........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Specialty Multi Drug Calibrator/Control LVL 2 ...........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Specialty Multi Drug Calibrator/Control LVL 3 ...........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
MP FC Emit Specialty Multi Drug Calibrator/Control LVL 4 ...........
Vial: 10 mL .......................
8/23/2016
Healthcare Diagnostics,
Pilot Emit II Plus Oxycodone Negative Control 100 .......................
4 mL–200
8/23/2016
Healthcare Diagnostics,
Pilot Emit II Plus Oxycodone Negative Control 300 .......................
4 mL–200
8/23/2016
Healthcare Diagnostics,
Pilot Emit II Plus Oxycodone Positive Control 100 .........................
4 mL–200
8/23/2016
Healthcare Diagnostics,
Pilot Emit II Plus Oxycodone Positive Control 300 .........................
4 mL–200
8/23/2016
Healthcare Diagnostics,
Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 1 ....
Pilot container:
mL.
Pilot container:
mL.
Pilot container:
mL.
Pilot container:
mL.
Pilot container:
mL.
4 mL–200
8/23/2016
Microgenics Corporation .............
Microgenics Corporation .............
Microgenics Corporation .............
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Microgenics Corporation .............
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
Siemens
Inc.
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
E:\FR\FM\12JNN1.SGM
12JNN1
26950
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
CHART I—Continued
Supplier
Product name
Form
Siemens Healthcare Diagnostics,
Inc.
Siemens Healthcare Diagnostics,
Inc.
Siemens Healthcare Diagnostics,
Inc.
USP .............................................
UTAK Laboratories, Inc ...............
Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 2 ....
USP Levomethorphan Solution Reference Standard .....................
AED II HR Serum Control, Ref: 72740 ...........................................
UTAK Laboratories, Inc ...............
AED II MR Serum Control, Ref: 72741 ...........................................
UTAK Laboratories, Inc ...............
Benzodiazepines 2 Serum Control HR, Ref: 22615 .......................
UTAK Laboratories, Inc ...............
Benzodiazepines 2 Serum Control MR, Ref: 22616 .......................
UTAK Laboratories, Inc ...............
Benzodiazepines Plus 100 Urine Control, Ref: 12090 ...................
UTAK Laboratories, Inc ...............
Benzodiazepines Plus 100 Whole Blood Control, Ref: 12092 .......
UTAK Laboratories, Inc ...............
Benzodiazepines Plus 400 ng/mL Urine Control, Ref: 12091 ........
UTAK Laboratories, Inc ...............
Clonazepam Serum Control HR, Ref: 22610 .................................
UTAK Laboratories, Inc ...............
Clonazepam Serum Control MR, Ref: 22611 .................................
UTAK Laboratories, Inc ...............
DHEA Plus High Serum Control, Ref: 51411 .................................
UTAK Laboratories, Inc ...............
DHEA Plus Low Serum Control, Ref: 51410 ..................................
UTAK Laboratories, Inc ...............
Pentobarbital Serum Control, Ref: 66319 .......................................
UTAK Laboratories, Inc ...............
Steroids Level 1 SMx Serum Control, Ref: 51401 .........................
UTAK Laboratories, Inc ...............
Steroids Level 2 SMx Serum Control, Ref: 51402 .........................
UTAK Laboratories, Inc ...............
Steroids Level 3 SMx Serum Control, Ref: 51403 .........................
UTAK Laboratories, Inc ...............
Steroids Level 4 SMx Serum Control, Ref: 51404 .........................
Pilot container: 4 mL–200
mL.
Pilot container: 4 mL–200
mL.
Pilot container: 4 mL–200
mL.
Box: 3 vials, 1.2 mL each
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 3 mL
each.
Carton: 5 bottles, 3 mL
each.
Carton: 5 bottles, 5 mL
each.
Carton: 5 bottles, 3 mL
each.
Carton: 5 bottles, 3 mL
each.
Carton: 5 bottles, 3 mL
each.
Carton: 5 bottles, 3 mL
each.
Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 3 ....
Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 4 ....
The Assistant Administrator has
found that each of the compounds,
mixtures, and preparations described in
Chart II below is not consistent with the
criteria stated in 21 U.S.C. 811(g)(3)(B)
and in 21 CFR 1308.23. Accordingly, the
Assistant Administrator has determined
that the chemical preparations or
mixtures generally described in Chart II
below and specifically described in the
application materials received by DEA,
are not exempt from application of any
Application
date
8/23/2016
8/23/2016
8/23/2016
9/13/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
12/27/2016
part of the CSA or from application of
any part of the CFR, with regard to the
requested exemption pursuant to 21
CFR 1308.23, as of the date that was
provided in the determination letters to
the individual requesters.
CHART II
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Supplier
Product name
Form
Aalto Scientific, Ltd ..................................
Biochemical Diagnostics, Inc ...................
Cerilliant Corporation ...............................
Cerilliant Corporation ...............................
Cerilliant Corporation ...............................
Cerilliant Corporation ...............................
Lipomed Inc .............................................
Lipomed Inc .............................................
Siemens Healthcare Diagnostics, Inc .....
Siemens Healthcare Diagnostics, Inc .....
Siemens Healthcare Diagnostics, Inc .....
Siemens Healthcare Diagnostics, Inc .....
Siemens Healthcare Diagnostics, Inc .....
Siemens Healthcare Diagnostics, Inc .....
Siemens Healthcare Diagnostics, Inc .....
General Chemistry Serum ..........................................................................
Detectabuse Custom Liquid Control Urine, MC253 ...................................
(±)-cis-3-Methylfentanyl HCl (0.1 mg/mL) ...................................................
(±)-cis-3-Methylfentanyl HCl (1 mg/mL) ......................................................
Butyryl fentanyl (0.1 mg/mL) ......................................................................
Butyryl fentanyl HCl (1 mg/mL) ..................................................................
Benzodiazepines mixture 8 (0.25 mg free base/mL acetonitrile) ...............
Estazolam (1 mg/mL methanol) .................................................................
BK Emit II Plus Oxycodone Negative Control 300 .....................................
BK Emit II Plus Oxycodone Positive Control 100 ......................................
BK Emit II Plus Oxycodone Positive Control 300 ......................................
BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 1 ..................
BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 2 ..................
BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 3 ..................
BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 4 ..................
Box: 1056 vials; 5 mL each .......
Glass vial: 1 mL–200 mL ..........
Glass ampule: 1 mL ..................
Glass ampule: 1 mL ..................
Glass ampule: 1 mL ..................
Glass ampule: 1 mL ..................
Glass ampule: 1 mL ..................
Glass ampule: 1 mL ..................
Bulk Container: 1 L–50 L ..........
Bulk Container: 1 L–50 L ..........
Bulk Container: 1 L–50 L ..........
Bulk Container: 1 L–50 L ..........
Bulk Container: 1 L–50 L ..........
Bulk Container: 1 L–50 L ..........
Bulk Container: 1 L–50 L ..........
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
E:\FR\FM\12JNN1.SGM
12JNN1
Application
date
6/20/2016
7/29/2016
6/21/2016
5/6/2016
6/21/2016
5/20/2016
10/28/2016
10/28/2016
8/23/2016
8/23/2016
8/23/2016
8/23/2016
8/23/2016
8/23/2016
8/23/2016
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
Scope of Approval
The exemptions are applicable only to
the precise preparation or mixture
described in the application submitted
to DEA in the form(s) listed in this order
and only for those sections of the CSA
and the CFR that are specifically
identified. In accordance with 21 CFR
1308.24(h), any change in the
quantitative or qualitative composition
of the preparation or mixture, or change
in the trade name or other designation
of the preparation or mixture after the
date of application requires a new
application. In accordance with 21 CFR
1308.24(g), the DEA may prescribe
requirements other than those set forth
in 1308.24(b)–(e) on a case-by-case basis
for materials exempted in bulk
quantities. Accordingly, in order to limit
opportunity for diversion from the
larger bulk quantities, the DEA has
determined that each of the exempted
bulk products listed in this order may
only be used in-house by the
manufacturer, and may not be
distributed for any purpose, or
transported to other facilities.
Additional exempt chemical
preparation requests received between
April 1, 2016, and December 31, 2016,
and not otherwise referenced in this
order may remain under consideration
until the DEA receives additional
information required, pursuant to 21
CFR 1308.23(d), as detailed in separate
correspondence to individual
requesters. The DEA’s order on such
requests will be communicated to the
public in a future Federal Register
publication.
The DEA also notes that these
exemptions are limited to exemption
from only those sections of the CSA and
the CFR that are specifically identified
in 21 CFR 1308.24(a). All other
requirements of the CSA and the CFR
apply, including registration as an
importer as required by 21 U.S.C. 957.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Opportunity for Comment
Pursuant to 21 CFR 1308.23, any
interested person may submit written
comments on or objections to any
chemical preparation in this order that
has been approved or denied as exempt.
If any comments or objections raise
significant issues regarding any finding
of fact or conclusion of law upon which
this order is based, the Assistant
Administrator will immediately
suspend the effectiveness of any
applicable part of this order until he
may reconsider the application in light
of the comments and objections filed.
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
Approved Exempt Chemical
Preparations Are Posted on DEA’s Web
Site
A list of all current exemptions,
including those listed in this order, is
available on the DEA’s Web site at
https://www.DEAdiversion.usdoj.gov/
schedules/exempt/exempt_chemlist.pdf.
The dates of applications of all current
exemptions are posted for easy
reference.
Dated: May 24, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–12110 Filed 6–9–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Mine Safety and Health Administration
[OMB Control No. 1219–0NEW]
Proposed Extension of Information
Collection; Performance Reports for
MSHA Grants
Mine Safety and Health
Administration, Labor.
ACTION: Request for public comments.
AGENCY:
The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden,
conducts a pre-clearance consultation
program to provide the general public
and Federal agencies with an
opportunity to comment on proposed
collections of information in accordance
with the Paperwork Reduction Act of
1995, 44 U.S.C. 3506(c)(2)(A). This
program helps to assure that requested
data can be provided in the desired
format, reporting burden (time and
financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements on respondents can be
properly assessed. Currently, the Mine
Safety and Health Administration
(MSHA) is soliciting comments on the
information collection for Performance
Reports for MSHA Grants.
DATES: All comments must be received
on or before August 11, 2017.
ADDRESSES: Comments concerning the
information collection requirements of
this notice may be sent by any of the
methods listed below.
• Federal E-Rulemaking Portal:
https://www.regulations.gov. Follow the
on-line instructions for submitting
comments for docket number MSHA–
2017–0007.
• Regular Mail: Send comments to
USDOL—MSHA, Office of Standards,
Regulations, and Variances, 201 12th
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
26951
Street South, Suite 4E401, Arlington,
VA 22202–5452.
• Hand Delivery: USDOL—Mine
Safety and Health Administration, 201
12th Street South, Suite 4E401,
Arlington, VA 22202–5452. Sign in at
the receptionist’s desk on the 4th floor
via the East elevator.
FOR FURTHER INFORMATION CONTACT:
Sheila McConnell, Director, Office of
Standards, Regulations, and Variances,
MSHA, at
MSHA.information.collections@dol.gov
(email); 202–693–9440 (voice); or 202–
693–9441 (facsimile).
SUPPLEMENTARY INFORMATION:
I. Background
Section 103(h) of the Federal Mine
Safety and Health Act of 1977 (Mine
Act), 30 U.S.C. 813(h), authorizes
MSHA to collect information necessary
to carry out its duty in protecting the
safety and health of miners. Further,
Sec. 101(a) of the Mine Act, 30 U.S.C.
811 authorizes the Secretary of Labor to
develop, promulgate, and revise as may
be appropriate, improved mandatory
health or safety standards for the
protection of life and prevention of
injuries in coal and metal and nonmetal
mines.
MSHA is requesting approval of a
new information collection for narrative
reporting of grant requirements. One of
MSHA’s strategic goals is to ‘‘improve
workplace safety and health’’ through
the strategic objective ‘‘secure safe and
healthy workplaces, particularly in
high-risk industries.’’ MSHA’s goal in
accomplishing this objective is to
‘‘prevent death, disease, and injury from
mining and promote safe and healthful
workplaces for the Nation’s miners.’’
Sec. 115 of the Mine Act, as amended,
requires mine operators to have a health
and safety training program. Under Sec.
503 of the Mine Act, as amended, the
Secretary may award grants to States to
assist in developing and enforcing State
mining laws and regulations, to improve
State workers’ compensation and
mining occupational disease laws and
programs, and to improve safety and
health conditions in the Nation’s mines
through Federal-State coordination and
cooperation.
Therefore, MSHA seeks the Office of
Management and Budget’s (OMB)
clearance of the information collections
the Department of Labor (DOL) requires
to carry out its grant program through
MSHA. This information collection
covers the performance reporting for
MSHA for Narrative Reports. MSHA is
seeking to transfer its DOL-approved
burden on the Narrative Reports under
OMB No. 1225–0086 to an MSHA
information collection.
E:\FR\FM\12JNN1.SGM
12JNN1
Agencies
[Federal Register Volume 82, Number 111 (Monday, June 12, 2017)]
[Notices]
[Pages 26944-26951]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12110]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-372]
Exempt Chemical Preparations Under the Controlled Substances Act
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Order with opportunity for comment.
-----------------------------------------------------------------------
SUMMARY: The applications for exempt chemical preparations received by
the Drug Enforcement Administration (DEA) between April 1, 2016, and
December 31, 2016, as listed below, were accepted for filing and have
been approved or denied as indicated.
DATES: Interested persons may file written comments on this order in
accordance with 21 CFR 1308.23(e). Electronic comments must be
submitted, and written comments must be postmarked, on or before August
11, 2017. Commenters should be aware that the electronic Federal Docket
Management System will not accept comments after 11:59 p.m. Eastern
Time on the last day of the comment period.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-372'' on all correspondence, including any
attachments.
Electronic comments: The Drug Enforcement Administration
(DEA) encourages that all comments be submitted through the Federal
eRulemaking Portal, which provides the ability to type short comments
directly into the comment field on the Web page or to attach a file for
lengthier comments. Please go to https://www.regulations.gov and follow
the online instructions at that site for submitting comments. Upon
completion of your submission you will receive a Comment Tracking
Number for your comment. Please be aware that submitted comments are
not instantaneously available for public view on Regulations.gov. If
you have received a comment tracking number, your comment has been
successfully submitted and there is no need to resubmit the same
comment.
Paper comments: Paper comments that duplicate the
electronic submission are not necessary and are discouraged. Should you
wish to mail a comment in lieu of an electronic comment, it should be
sent via regular or express mail to: Drug Enforcement Administration,
Attention: DEA Federal Register Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control
[[Page 26945]]
Division, Drug Enforcement Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-
6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received are considered part of the
public record and made available for public inspection online at https://www.regulations.gov and in the DEA's public docket. Such information
includes personal identifying information (such as your name, address,
etc.) voluntarily submitted by the commenter.
If you want to submit personal identifying information (such as
your name, address, etc.) as part of your comment, but do not want it
to be posted online or made available in the public docket, you must
include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first
paragraph of your comment. You must also place all the personal
identifying information you do not want posted online or made available
in the public docket in the first paragraph of your comment and
identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be posted online or made available
in the public docket, you must include the phrase ``CONFIDENTIAL
BUSINESS INFORMATION'' in the first paragraph of your comment. You must
also prominently identify confidential business information to be
redacted within the comment.
Comments containing personal identifying information and
confidential business information identified as directed above will
generally be made publicly available in redacted form. If a comment has
so much confidential business information that it cannot be effectively
redacted, all or part of that comment may not be made publicly
available. Comments posted to https://www.regulations.gov may include
any personal identifying information (such as name, address, and phone
number) included in the text of your electronic submission that is not
identified as directed above as confidential.
An electronic copy of this document is available at https://www.regulations.gov for easy reference.
Legal Authority
The Drug Enforcement Administration (DEA) implements and enforces
titles II and III of the Comprehensive Drug Abuse Prevention and
Control Act of 1970, as amended. Titles II and II are referred to as
the ``Controlled Substances Act'' and the ``Controlled Substances
Import and Export Act,'' or the ``CSA'' for the purpose of this action.
21 U.S.C. 801-971. The DEA publishes the implementing regulations for
these statutes in title 21 of the Code of Federal Regulations (CFR),
chapter II.
The CSA and its implementing regulations are designed to prevent,
detect, and eliminate the diversion of controlled substances and listed
chemicals into the illicit market while ensuring an adequate supply is
available for the legitimate medical, scientific, research, and
industrial needs of the United States. Controlled substances have the
potential for abuse and dependence and are controlled to protect the
public health and safety.
Section 201 of the CSA (21 U.S.C. 811) authorizes the Attorney
General, by regulation, to exempt from certain provisions of the CSA
certain compounds, mixtures, or preparations containing a controlled
substance, if he finds that such compounds, mixtures, or preparations
meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).\1\ The DEA
regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria
by which the DEA Assistant Administrator may exempt a chemical
preparation or mixture from certain provisions of the CSA. The
Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or
revoke the criteria by which exemptions are granted and modify the
scope of exemptions at any time.
---------------------------------------------------------------------------
\1\ This authority has been delegated from the Attorney General
to the Administrator of the DEA by 28 CFR 0.100, and subsequently
redelegated to the Deputy Assistant Administrator pursuant to
Section 7 of 28 CFR 0.104, Appendix to Subpart R.
---------------------------------------------------------------------------
Exempt Chemical Preparation Applications Submitted Between April 1,
2016, and December 31, 2016
The Assistant Administrator received applications between April 1,
2016, and December 31, 2016, requesting exempt chemical preparation
status detailed in 21 CFR 1308.23. Pursuant to the criteria stated in
21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant
Administrator has found that each of the compounds, mixtures, and
preparations described in Chart I below is intended for laboratory,
industrial, educational, or special research purposes and not for
general administration to a human being or animal and either: (1)
Contains no narcotic controlled substance and is packaged in such a
form or concentration that the packaged quantity does not present any
significant potential for abuse; or (2) contains either a narcotic or
non-narcotic controlled substance and one or more adulterating or
denaturing agents in such a manner, combination, quantity, proportion,
or concentration that the preparation or mixture does not present any
potential for abuse; if the preparation or mixture contains a narcotic
controlled substance, it must be formulated in such a manner that it
incorporates methods of denaturing or other means so that the
preparation or mixture is not liable to be abused or have ill effects
if abused, and so that the narcotic substance cannot in practice be
removed.
Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23,
and 21 CFR 1308.24, the Assistant Administrator has determined that
each of the chemical preparations or mixtures generally described in
Chart I below and specifically described in the application materials
received by the DEA, is exempt, to the extent described in 21 CFR
1308.24, from application of sections 302, 303, 305, 306, 307, 308,
309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of
the CSA, and 21 CFR 1301.74, as of the date that was provided in the
approval letters to the individual requesters.
Chart I
----------------------------------------------------------------------------------------------------------------
Application
Supplier Product name Form date
----------------------------------------------------------------------------------------------------------------
Aalto Scientific, Ltd.................. Endocrine Program.............. Amber vial: 5 mL......... 8/23/2016
Aalto Scientific, Ltd.................. Endocrinology.................. Amber vial: 5 mL......... 8/23/2016
Aalto Scientific, Ltd.................. Linearity FD Testosterone, Kit: 5 vials; 3 mL each.. 12/7/2016
Siemens Centaur.
Absolute Standards, Inc................ ISO G34 Calibrator Spike High.. Glass ampoule: 1 mL...... 8/3/2016
Absolute Standards, Inc................ ISO G34 Calibrator Spike Low... Glass ampoule: 1 mL...... 8/3/2016
Absolute Standards, Inc................ ISO G34 Calibrator Spike Glass ampoule: 1 mL...... 8/3/2016
Solution.
[[Page 26946]]
Absolute Standards, Inc................ ISO G34 Internal Standard...... Glass ampoule: 1 mL...... 8/3/2016
Accriva Diagnostics, Inc............... Hemochron PT................... Box: 45 cuvettes; 5/17/2016
7.5[mu]L each.
Arbor Assays........................... Testosterone 5-pack Enzyme Kit: 400 [mu]L vial...... 10/18/2016
Immunoassay Kit (K032-H5).
Arbor Assays........................... Testosterone Enzyme Immunoassay Kit: 1 mL vial........... 10/18/2016
Kit (ISWE001).
Arbor Assays........................... Testosterone Enzyme Immunoassay Kit: 90 [mu]L vial....... 10/18/2016
Kit (K032-H1).
Arbor Assays........................... Testosterone Standard (1,000 ng/ Plastic vial: 1 mL....... 10/18/2016
mL).
Arbor Assays........................... Testosterone Standard (200,000 Plastic vial: 90 [mu]L... 10/18/2016
pg/mL).
Arbor Assays........................... Testosterone Standard (200,000 Plastic vial: 400 [mu]L.. 10/18/2016
pg/mL).
Biochemical Diagnostics, Inc........... Detectabuse Custom Liquid Glass vial: 1 mL-200 mL.. 7/29/2016
Control Urine, MC252.
Biochemical Diagnostics, Inc........... Detectabuse Custom Liquid Glass vials: 1 ml-200 mL. 9/30/2016
Control Urine, MC253.
Biochemical Diagnostics, Inc........... Detectabuse Custom Liquid Glass vial: 1 mL-200 mL.. 7/29/2016
Control Urine, MC254.
Biochemical Diagnostics, Inc........... Detectabuse Custom Liquid Glass vial: 1 mL-200 mL.. 7/29/2016
Control Urine, MC255.
Biochemical Diagnostics, Inc........... Detectabuse Custom Liquid Glass vials: 1 ml-200 mL. 12/19/2016
Control Urine, MC256.
Biochemical Diagnostics, Inc........... Detectabuse Custom Liquid Glass vials: 1 ml-200 mL. 12/19/2016
Control Urine, MC257.
Cayman Chemical Company................ 11-Keto Testosterone CRM; 1 mg/ Glass ampule: 1 mL....... 6/28/2016
mL in Acetonitrile.
Cayman Chemical Company................ AB-CHMINACA (CRM); 1 mg/mL in Glass ampule: 1 mL....... 8/26/2016
Acetonitrile.
Cayman Chemical Company................ AB-CHMINACA (CRM); 1 mg/mL in Glass ampule: 1 mL....... 8/26/2016
Methanol.
Cayman Chemical Company................ AB-CHMINACA (CRM); 100 [micro]g/ Glass ampule: 1 mL....... 8/26/2016
mL in Acetonitrile.
Cayman Chemical Company................ AB-CHMINACA (CRM); 100 [micro]g/ Glass ampule: 1 mL....... 8/26/2016
mL in Methanol.
Cayman Chemical Company................ AB-PINACA CRM; 1 mg/mL in Glass ampule: 1 mL....... 6/28/2016
Methanol.
Cayman Chemical Company................ Acetyl Fentanyl CRM; 1 mg/mL in Glass ampule: 1 mL....... 6/28/2016
Methanol.
Cayman Chemical Company................ Acetyl Fentanyl CRM; 100 Glass ampule: 1 mL....... 6/28/2016
[micro]g/mL in Methanol.
Cayman Chemical Company................ Cocaine CRM; 1 mg/mL in Glass ampule: 1 mL....... 6/28/2016
Acetonitrile.
Cayman Chemical Company................ Cocaine/Heroin/Methamphetamine Glass ampule: 1 mL....... 8/26/2016
Mixture CRM; 1 mg/mL each in
Acetonitrile.
Cayman Chemical Company................ Cocaine/Heroin/Methamphetamine Glass ampule: 1 mL....... 8/26/2016
Mixture CRM; 100 [micro]g/mL
each in Acetonitrile.
Cayman Chemical Company................ Cocaine/Heroin/Methamphetamine Glass ampule: 1 mL....... 8/26/2016
Mixture CRM; 250 [micro]g/mL
each in Acetonitrile.
Cayman Chemical Company................ Cocaine/Heroin/Methamphetamine Glass ampule: 1 mL....... 8/26/2016
Mixture CRM; 500 [micro]g/mL
each in Acetonitrile.
Cayman Chemical Company................ GC-MS Drug Standard Mixture 1 Glass ampule: 1 mL....... 6/28/2016
in Acetonitrile.
Cayman Chemical Company................ Phytocannabinoid Mixture 1; 1 Glass ampule: 1 mL....... 6/28/2016
mg/mL in Acetonitrile.
Cayman Chemical Company................ Tapentadol (hydrochloride) CRM; Glass ampule: 1 mL....... 8/26/2016
1 mg/mL in Acetonitrile.
Cayman Chemical Company................ Tapentadol (hydrochloride) CRM; Glass ampule: 1 mL....... 8/26/2016
1 mg/mL in Methanol.
Cayman Chemical Company................ Tapentadol (hydrochloride) CRM; Glass ampule: 1 mL....... 8/26/2016
100 [micro]g/mL in
Acetonitrile.
Cayman Chemical Company................ Tapentadol (hydrochloride) CRM; Glass ampule: 1 mL....... 8/26/2016
100 [micro]g/mL in Methanol.
Cayman Chemical Company................ THJ2201 (CRM); 1 mg/mL in Glass ampule: 1 mL....... 8/26/2016
Acetonitrile.
Cayman Chemical Company................ THJ2201 (CRM); 1 mg/mL in Glass ampule: 1 mL....... 8/26/2016
Methanol.
Cayman Chemical Company................ THJ2201 (CRM); 100 [micro]g/mL Glass ampule: 1 mL....... 8/26/2016
in Acetonitrile.
Cayman Chemical Company................ THJ2201 (CRM); 100 [micro]g/mL Glass ampule: 1 mL....... 8/26/2016
in Methanol.
Cayman Chemical Company................ ToxBox THC/THC Metabolite Plate 48-well plate............ 6/28/2016
Cerilliant Corporation................. ()-11-Hydroxy- Glass ampule: 1 mL....... 11/11/2016
delta9-THC glucuronide (0.01
mg/mL).
Cerilliant Corporation................. ()-Cannabicyclol Glass ampule: 1.0 mL..... 7/18/2016
(1.0 mg/mL).
Cerilliant Corporation................. ()-cis-3- Glass ampule: 1 mL....... 6/21/2016
Methylfentanyl HCl (0.05 mg/
mL).
Cerilliant Corporation................. ()-cis-3- Glass ampule: 0.5 mL..... 7/18/2016
Methylfentanyl HCl (0.1 mg/mL).
Cerilliant Corporation................. 5alpha-Dihydrotestosterone-D3 Glass ampule: 1 mL....... 9/28/2016
[16, 16, 17-D3]; 10 [micro]g/
mL.
Cerilliant Corporation................. 6beta-Naltrexol (1 mg/mL)...... Glass ampule: 1 mL....... 5/6/2016
Cerilliant Corporation................. AH-7921 HCl (1 mg/mL).......... Glass ampule: 1 mL....... 5/20/2016
Cerilliant Corporation................. AH-7921-D3 HCl (0.1 mg/mL)..... Glass ampule: 1 mL....... 5/20/2016
Cerilliant Corporation................. Brivaracetam-D3 (0.1 mg/mL).... Glass ampule: 1 mL....... 11/30/2016
Cerilliant Corporation................. Butyryl fentanyl (0.05 mg/mL).. Glass ampule: 1 mL....... 6/21/2016
Cerilliant Corporation................. Butyryl fentanyl (0.1 mg/mL)... Glass ampule: 0.5 mL..... 7/18/2016
Cerilliant Corporation................. Cannabichromenic acid (CBCA) Glass ampule: 1 mL....... 11/30/2016
(1.0 mg/mL).
Cerilliant Corporation................. Cannabicyclolic acid (CBLA) Glass ampule: 1 mL....... 11/30/2016
(1.0 mg/mL).
Cerilliant Corporation................. Carfentanil (0.1 mg/mL)........ Glass ampule: 0.5 mL..... 9/28/2016
Cerilliant Corporation................. Carfentanil oxalate (0.1 mg/mL) Glass ampule: 0.5 mL..... 11/30/2016
Cerilliant Corporation................. Carfentanil-D5 oxalate (0.1 mg/ Glass ampule: 0.5 mL..... 11/30/2016
mL).
Cerilliant Corporation................. Clorazepate dipotassium (1 mg/ Glass ampule: 1 mL....... 5/6/2016
mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 1 (20 pg/mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 2 (50 pg/mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 3 (100 pg/mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 4 (500 pg/mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 5 (1000 pg/mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 6 (2500 pg/mL).
Cerilliant Corporation................. Dihydrotestosterone Calibrator Cryovial: 1 mL........... 8/12/2016
Level 7 (10 ng/mL).
Cerilliant Corporation................. Diphenoxylate HCl (1 mg/mL).... Glass ampule: 1 mL....... 5/20/2016
Cerilliant Corporation................. Furanyl fentanyl (0.1 mg/mL)... Glass ampule: 0.5 mL..... 11/30/2016
Cerilliant Corporation................. Norhydromorphone-D3 HCl (0.1 mg/ Glass ampule: 1.0 mL..... 7/18/2016
mL).
Cerilliant Corporation................. Noroxymorphone-D3 HCl (0.1 mg/ Glass ampule: 1.0 mL..... 7/18/2016
mL).
[[Page 26947]]
Cerilliant Corporation................. Pholcodine (1 mg/mL)........... Glass ampule: 1 mL....... 5/6/2016
Cerilliant Corporation................. Tapentadol-D3 HCl (1 mg/mL).... Glass ampule: 1 mL....... 11/11/2016
Cerilliant Corporation................. U-47700 (1.0 mg/mL)............ Glass ampule: 1 mL....... 11/30/2016
IDEXX Laboratories..................... Coag Dx PT..................... Box: 10 cartridges; 10/21/2016
7.5[mu]L each.
IDEXX Laboratories..................... Coag Dx PT Cartridge........... Cartridges: 7.5[mu]L each 10/21/2016
Immunalysis Corporation................ cTHC Urine Calibrator 1 (20 ng/ Dropper bottle: 5 mL, 15 5/27/2016
mL). mL.
Immunalysis Corporation................ cTHC Urine Calibrator 2 (50 ng/ Dropper bottle: 5 mL, 15 5/27/2016
mL). mL.
Immunalysis Corporation................ cTHC Urine Calibrator 3 (100 ng/ Dropper bottle: 5 mL, 15 5/27/2016
mL). mL.
Immunalysis Corporation................ cTHC Urine Calibrator 4 (200 ng/ Dropper bottle: 5 mL, 15 5/27/2016
mL). mL.
Immunalysis Corporation................ cTHC Urine Control HIGH (62.5 Dropper bottle: 5 mL, 15 5/27/2016
ng/mL). mL.
Immunalysis Corporation................ cTHC Urine Control LOW (37.5 ng/ Dropper bottle: 5 mL, 15 5/27/2016
mL). mL.
Immunalysis Corporation................ Fentanyl Urine Calibrator 1 (1 Dropper bottle: 5 mL..... 5/27/2016
ng/mL).
Immunalysis Corporation................ Fentanyl Urine Calibrator 2 (2 Dropper bottle: 5 mL..... 5/27/2016
ng/mL).
Immunalysis Corporation................ Fentanyl Urine Calibrator 3 (4 Dropper bottle: 5 mL..... 5/27/2016
ng/mL).
Immunalysis Corporation................ Fentanyl Urine Control HIGH Dropper bottle: 5 mL..... 5/27/2016
(1.5 ng/mL).
Immunalysis Corporation................ Fentanyl Urine Control LOW (0.5 Dropper bottle: 5 mL..... 5/27/2016
ng/mL).
Immunalysis Corporation................ MDC Calibrator 1............... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Calibrator 2............... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Calibrator 3............... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Calibrator 4............... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Control HIGH Set 1......... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Control HIGH Set 1......... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Control LOW Set 1.......... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ MDC Control LOW Set 2.......... Dropper bottle: 15 mL, 25 5/27/2016
mL.
Immunalysis Corporation................ Opiates Urine Calibrator 2000 1 Dropper bottle: 5 mL, 15 5/27/2016
(1000 ng/mL). mL.
Immunalysis Corporation................ Opiates Urine Calibrator 2000 2 Dropper bottle: 5 mL, 15 5/27/2016
(2000 ng/mL). mL.
Immunalysis Corporation................ Opiates Urine Calibrator 2000 3 Dropper bottle: 5 mL, 15 5/27/2016
(4000 ng/mL). mL.
Immunalysis Corporation................ Opiates Urine Calibrator 2000 4 Dropper bottle: 5 mL, 15 5/27/2016
(6000 ng/mL). mL.
Immunalysis Corporation................ Oxazepam Urine Control HIGH Dropper bottle: 5 mL, 15 5/27/2016
(125 ng/mL). mL.
Immunalysis Corporation................ Oxazepam Urine Control LOW (75 Dropper bottle: 5 mL, 15 5/27/2016
ng/mL). mL.
Instrumentation Laboratory............. Gem Test PT.................... Box: 45 cuvettes; 10/6/2016
7.5[mu]L each.
IsoSciences, LLC....................... Codeine-[13C4, 15N], 1000 [mu]g/ Amber ampule: 1 mL....... 10/20/2016
mL in methanol.
IsoSciences, LLC....................... Codeine-6[beta]-Glucuronide- Amber ampule: 1 mL....... 10/20/2016
[13C10, 15N], 1000 [mu]g/mL in
methanol:water (2:8).
IsoSciences, LLC....................... Morphine-[13C4, 15N], 1000 Amber ampule: 1 mL....... 10/20/2016
[mu]g/mL in methanol.
IsoSciences, LLC....................... Morphine-6[beta]-Glucuronide- Amber ampule: 1 mL....... 10/20/2016
[13C10, 15N], 1000 [mu]g/mL in
methanol:water (2:8).
IsoSciences, LLC....................... Testosterone-[2H8], 100 Amber Ampule: 1 mL....... 8/10/2016
[micro]g/mL in methanol.
IsoSciences, LLC....................... Testosterone-[2H8], 1000 Amber Ampule: 1 mL....... 8/10/2016
[micro]g/mL in methanol.
ITC.................................... Hemochron Jr................... Box: 45 cuvettes; 7/1/2016
7.5[mu]L each.
Lipomed Inc............................ 25B-NB2OMe (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ 25C-NB2OMe (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ 25I-NB2OMe (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ 25I-NB2OMe-D9 (0.1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ 25I-NB2OMe-D9 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ 3,4-Methylendioxypyrovalerone Glass ampule: 1 mL....... 10/28/2016
(1 mg/mL methanol).
Lipomed Inc............................ 3,4-Methylenedioxy-[alpha]- Glass ampule: 1 mL....... 10/28/2016
pyrrolidinopropiophenone (1 mg/
mL methanol).
[[Page 26948]]
Lipomed Inc............................ 3-Desmethylprodine (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
acetonitrile).
Lipomed Inc............................ 4-Ethylmethcathinone (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ 4-Methylethcathinone (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ 4-Methylmethcathinone (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ 4-Methylmethcathinone-D3 (0.1 Glass ampule: 1 mL....... 10/28/2016
mg/mL methanol).
Lipomed Inc............................ 4-Methylmethcathinone-D3 (1 mg/ Glass ampule: 1 mL....... 10/28/2016
mL methanol).
Lipomed Inc............................ Benzodiazepines mixture (.001 Glass ampule: 1 mL....... 10/28/2016
mg free base/ml acetonitrile).
Lipomed Inc............................ Benzodiazepines mixture 5 (1 mg Glass ampule: 1 mL....... 10/28/2016
free base/mL acetonitrile).
Lipomed Inc............................ Bufotenine.oxalate.monohydrate Glass ampule: 1 mL....... 10/28/2016
(1 mg/mL methanol).
Lipomed Inc............................ Butabarbital (1 mg/mL methanol) Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Butalbital (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Butalbital-D5 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Butylone (1 mg/mL methanol).... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Cannabidiol-D3 (0.1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Cannabidiol-D3 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Cannabinol-D3 (0.1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Cannabinol-D3 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Carisoprodol (1 mg/mL methanol) Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Clotiazepam (1 mg/mL methanol). Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Cocaethylene-D3 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
acetonitrile).
Lipomed Inc............................ Cocaine mixture 2 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Desomorphine (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
acetonitrile).
Lipomed Inc............................ Ethylone (1 mg/mL methanol).... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-018 (0.1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-018 (1 mg/mL methanol)..... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-018-D11 metabolite (0.1 mg/ Glass ampule: 1 mL....... 10/28/2016
mL methanol).
Lipomed Inc............................ JWH-018-D11 metabolite (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ JWH-019 (0.1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-019 (1 mg/mL methanol)..... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-081 (0.1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-081 (1 mg/mL methanol)..... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-122 (0.1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-122 (1 mg/mL methanol)..... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-200 (0.1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ JWH-200 (1 mg/mL methanol)..... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ L-Methamphetamine (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Loprazolam (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Mazindol (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
Dimethylformamide).
Lipomed Inc............................ Meprobamate (1 mg/mL methanol). Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Methandienone (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Methylone (1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Methylone-D3 (0.1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Methylone-D3 (1 mg/mL methanol) Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ N,N-Dimethylamphetamine (1 mg/ Glass ampule: 1 mL....... 10/28/2016
mL methanol).
Lipomed Inc............................ Naphyrone (1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Nimetazepam (1 mg/mL methanol). Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Norbuprenorphine (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Normeperidine (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Pentedrone (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Pentylone (1 mg/mL methanol)... Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Phenobarbital-D5 (side chain) Glass ampule: 1 mL....... 10/28/2016
(0.1 mg/mL methanol).
Lipomed Inc............................ Phenobarbital-D5 (side chain) Glass ampule: 1 mL....... 10/28/2016
(1 mg/mL methanol).
Lipomed Inc............................ Pregabalin (1 mg/mL methanol).. Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ Propoxyphen-D5 (0.1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Propoxyphen-D5 (1 mg/mL Glass ampule: 1 mL....... 10/28/2016
methanol).
Lipomed Inc............................ Pyrovalerone (1 mg/mL methanol) Glass ampule: 1 mL....... 10/28/2016
Lipomed Inc............................ [alpha]- Glass ampule: 1 mL....... 10/28/2016
Pyrrolidinopropiophenone (1 mg/
mL methanol).
Lipomed Inc............................ [alpha]- Glass ampule: 1 mL....... 10/28/2016
Pyrrolidinovalerophenone (1 mg/
mL methanol).
Microgenics Corporation................ Cascadion SM Total Testosterone Box: 8 bottles, 29 mL 12/16/2016
Internal Standard. each.
Microgenics Corporation................ Cedia Buprenorphine OFT Control Vial: 10 mL; Box: 2 vials 11/15/2016
Set (Low and High) Catalog
Number: 10022377.
Microgenics Corporation................ Cedia Buprenorphine OFT Cutoff Vial: 5 mL; Box: 1 vial.. 11/15/2016
Calibrator Catalog Number:
10022376.
Microgenics Corporation................ Cedia Multi-Drug OFT Cutoff Vial: 10 mL; Box: 1 vial. 10/20/2016
Calibrator Set B Catalog
Number: 10022355.
Microgenics Corporation................ Cedia Multi-Drug OFT Cutoff Vial: 15 mL; Box: 2 vials 10/20/2016
Control Set B (Low and High)
Catalog Number: 10022356.
Microgenics Corporation................ Intercept i2he Multi-Drug Oral Vial: 10 mL; Box: 1 vial. 10/19/2016
Fluid Cutoff Calibrator Set B
Catalog Number: 1001-0419.
Microgenics Corporation................ Intercept i2he Multi-Drug Oral Vial: 15 mL; Box: 2 vials 10/19/2016
Fluid Cutoff Control Set B
(Low and High) Catalog Number:
1001-0420.
[[Page 26949]]
Microgenics Corporation................ Thermo Scientific CEDIA Vial: 5 mL Box: 1 vial... 8/30/2016
Buprenorphine II Calibrator 10
ng/mL Catalog Number: 10020799.
Microgenics Corporation................ Thermo Scientific CEDIA Vial: 5 mL Box: 1 vial... 8/30/2016
Buprenorphine II Calibrator
100 ng/mL Catalog Number:
10020802.
Microgenics Corporation................ Thermo Scientific CEDIA Vial: 5 mL Box: 1 vial... 8/30/2016
Buprenorphine II Calibrator 20
ng/mL Catalog Number: 10020800.
Microgenics Corporation................ Thermo Scientific CEDIA Vial: 5 mL Box: 1 vial... 8/30/2016
Buprenorphine II Calibrator 50
ng/mL Catalog Number: 10020801.
Microgenics Corporation................ Thermo Scientific CEDIA Vial: 5 mL Box: 4 vials.. 8/30/2016
Buprenorphine II Controls (Low
and High) Catalog Number:
10020804.
Siemens Healthcare Diagnostics, Inc.... BK Emit II Plus Oxycodone Bulk Container: 1 L-50 L. 8/23/2016
Negative Control 100.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Oxycodone Negative Vial: 10 mL.............. 8/23/2016
Control 100.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Oxycodone Negative Vial: 10 mL.............. 8/23/2016
Control 300.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Oxycodone Positive Vial: 10 mL.............. 8/23/2016
Control 100.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Oxycodone Positive Vial: 10 mL.............. 8/23/2016
Control 300.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
1.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
2.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
3.
Siemens Healthcare Diagnostics, Inc.... Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
4.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Oxycodone Vial: 10 mL.............. 8/23/2016
Negative Control 100.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Oxycodone Vial: 10 mL.............. 8/23/2016
Negative Control 300.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Oxycodone Vial: 10 mL.............. 8/23/2016
Positive Control 100.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Oxycodone Vial: 10 mL.............. 8/23/2016
Positive Control 300.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
1.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
2.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
3.
Siemens Healthcare Diagnostics, Inc.... FC Emit II Plus Specialty Multi Vial: 10 mL.............. 8/23/2016
Drug Calibrator/Control Level
4.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Oxycodone Negative Vial: 10 mL.............. 8/23/2016
Control 100.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Oxycodone Negative Vial: 10 mL.............. 8/23/2016
Control 300.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Oxycodone Positive Vial: 10 mL.............. 8/23/2016
Control 100.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Oxycodone Positive Vial: 10 mL.............. 8/23/2016
Control 300.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Specialty Multi Drug Vial: 10 mL.............. 8/23/2016
Calibrator/Control LVL 1.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Specialty Multi Drug Vial: 10 mL.............. 8/23/2016
Calibrator/Control LVL 2.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Specialty Multi Drug Vial: 10 mL.............. 8/23/2016
Calibrator/Control LVL 3.
Siemens Healthcare Diagnostics, Inc.... MP FC Emit Specialty Multi Drug Vial: 10 mL.............. 8/23/2016
Calibrator/Control LVL 4.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Oxycodone Pilot container: 4 mL-200 8/23/2016
Negative Control 100. mL.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Oxycodone Pilot container: 4 mL-200 8/23/2016
Negative Control 300. mL.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Oxycodone Pilot container: 4 mL-200 8/23/2016
Positive Control 100. mL.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Oxycodone Pilot container: 4 mL-200 8/23/2016
Positive Control 300. mL.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Specialty Pilot container: 4 mL-200 8/23/2016
Multi Drug Calibrator/Control mL.
LVL 1.
[[Page 26950]]
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Specialty Pilot container: 4 mL-200 8/23/2016
Multi Drug Calibrator/Control mL.
LVL 2.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Specialty Pilot container: 4 mL-200 8/23/2016
Multi Drug Calibrator/Control mL.
LVL 3.
Siemens Healthcare Diagnostics, Inc.... Pilot Emit II Plus Specialty Pilot container: 4 mL-200 8/23/2016
Multi Drug Calibrator/Control mL.
LVL 4.
USP.................................... USP Levomethorphan Solution Box: 3 vials, 1.2 mL each 9/13/2016
Reference Standard.
UTAK Laboratories, Inc................. AED II HR Serum Control, Ref: Carton: 5 bottles, 5 mL 12/27/2016
72740. each.
UTAK Laboratories, Inc................. AED II MR Serum Control, Ref: Carton: 5 bottles, 5 mL 12/27/2016
72741. each.
UTAK Laboratories, Inc................. Benzodiazepines 2 Serum Control Carton: 5 bottles, 5 mL 12/27/2016
HR, Ref: 22615. each.
UTAK Laboratories, Inc................. Benzodiazepines 2 Serum Control Carton: 5 bottles, 5 mL 12/27/2016
MR, Ref: 22616. each.
UTAK Laboratories, Inc................. Benzodiazepines Plus 100 Urine Carton: 5 bottles, 5 mL 12/27/2016
Control, Ref: 12090. each.
UTAK Laboratories, Inc................. Benzodiazepines Plus 100 Whole Carton: 5 bottles, 5 mL 12/27/2016
Blood Control, Ref: 12092. each.
UTAK Laboratories, Inc................. Benzodiazepines Plus 400 ng/mL Carton: 5 bottles, 5 mL 12/27/2016
Urine Control, Ref: 12091. each.
UTAK Laboratories, Inc................. Clonazepam Serum Control HR, Carton: 5 bottles, 5 mL 12/27/2016
Ref: 22610. each.
UTAK Laboratories, Inc................. Clonazepam Serum Control MR, Carton: 5 bottles, 5 mL 12/27/2016
Ref: 22611. each.
UTAK Laboratories, Inc................. DHEA Plus High Serum Control, Carton: 5 bottles, 3 mL 12/27/2016
Ref: 51411. each.
UTAK Laboratories, Inc................. DHEA Plus Low Serum Control, Carton: 5 bottles, 3 mL 12/27/2016
Ref: 51410. each.
UTAK Laboratories, Inc................. Pentobarbital Serum Control, Carton: 5 bottles, 5 mL 12/27/2016
Ref: 66319. each.
UTAK Laboratories, Inc................. Steroids Level 1 SMx Serum Carton: 5 bottles, 3 mL 12/27/2016
Control, Ref: 51401. each.
UTAK Laboratories, Inc................. Steroids Level 2 SMx Serum Carton: 5 bottles, 3 mL 12/27/2016
Control, Ref: 51402. each.
UTAK Laboratories, Inc................. Steroids Level 3 SMx Serum Carton: 5 bottles, 3 mL 12/27/2016
Control, Ref: 51403. each.
UTAK Laboratories, Inc................. Steroids Level 4 SMx Serum Carton: 5 bottles, 3 mL 12/27/2016
Control, Ref: 51404. each.
----------------------------------------------------------------------------------------------------------------
The Assistant Administrator has found that each of the compounds,
mixtures, and preparations described in Chart II below is not
consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21
CFR 1308.23. Accordingly, the Assistant Administrator has determined
that the chemical preparations or mixtures generally described in Chart
II below and specifically described in the application materials
received by DEA, are not exempt from application of any part of the CSA
or from application of any part of the CFR, with regard to the
requested exemption pursuant to 21 CFR 1308.23, as of the date that was
provided in the determination letters to the individual requesters.
Chart II
----------------------------------------------------------------------------------------------------------------
Application
Supplier Product name Form date
----------------------------------------------------------------------------------------------------------------
Aalto Scientific, Ltd................... General Chemistry Serum...... Box: 1056 vials; 5 mL each 6/20/2016
Biochemical Diagnostics, Inc............ Detectabuse Custom Liquid Glass vial: 1 mL-200 mL... 7/29/2016
Control Urine, MC253.
Cerilliant Corporation.................. ()-cis-3- Glass ampule: 1 mL........ 6/21/2016
Methylfentanyl HCl (0.1 mg/
mL).
Cerilliant Corporation.................. ()-cis-3- Glass ampule: 1 mL........ 5/6/2016
Methylfentanyl HCl (1 mg/mL).
Cerilliant Corporation.................. Butyryl fentanyl (0.1 mg/mL). Glass ampule: 1 mL........ 6/21/2016
Cerilliant Corporation.................. Butyryl fentanyl HCl (1 mg/ Glass ampule: 1 mL........ 5/20/2016
mL).
Lipomed Inc............................. Benzodiazepines mixture 8 Glass ampule: 1 mL........ 10/28/2016
(0.25 mg free base/mL
acetonitrile).
Lipomed Inc............................. Estazolam (1 mg/mL methanol). Glass ampule: 1 mL........ 10/28/2016
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Oxycodone Bulk Container: 1 L-50 L.. 8/23/2016
Negative Control 300.
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Oxycodone Bulk Container: 1 L-50 L.. 8/23/2016
Positive Control 100.
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Oxycodone Bulk Container: 1 L-50 L.. 8/23/2016
Positive Control 300.
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Specialty Bulk Container: 1 L-50 L.. 8/23/2016
Multi Drug Calibrator/
Control LVL 1.
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Specialty Bulk Container: 1 L-50 L.. 8/23/2016
Multi Drug Calibrator/
Control LVL 2.
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Specialty Bulk Container: 1 L-50 L.. 8/23/2016
Multi Drug Calibrator/
Control LVL 3.
Siemens Healthcare Diagnostics, Inc..... BK Emit II Plus Specialty Bulk Container: 1 L-50 L.. 8/23/2016
Multi Drug Calibrator/
Control LVL 4.
----------------------------------------------------------------------------------------------------------------
[[Page 26951]]
Scope of Approval
The exemptions are applicable only to the precise preparation or
mixture described in the application submitted to DEA in the form(s)
listed in this order and only for those sections of the CSA and the CFR
that are specifically identified. In accordance with 21 CFR 1308.24(h),
any change in the quantitative or qualitative composition of the
preparation or mixture, or change in the trade name or other
designation of the preparation or mixture after the date of application
requires a new application. In accordance with 21 CFR 1308.24(g), the
DEA may prescribe requirements other than those set forth in
1308.24(b)-(e) on a case-by-case basis for materials exempted in bulk
quantities. Accordingly, in order to limit opportunity for diversion
from the larger bulk quantities, the DEA has determined that each of
the exempted bulk products listed in this order may only be used in-
house by the manufacturer, and may not be distributed for any purpose,
or transported to other facilities.
Additional exempt chemical preparation requests received between
April 1, 2016, and December 31, 2016, and not otherwise referenced in
this order may remain under consideration until the DEA receives
additional information required, pursuant to 21 CFR 1308.23(d), as
detailed in separate correspondence to individual requesters. The DEA's
order on such requests will be communicated to the public in a future
Federal Register publication.
The DEA also notes that these exemptions are limited to exemption
from only those sections of the CSA and the CFR that are specifically
identified in 21 CFR 1308.24(a). All other requirements of the CSA and
the CFR apply, including registration as an importer as required by 21
U.S.C. 957.
Opportunity for Comment
Pursuant to 21 CFR 1308.23, any interested person may submit
written comments on or objections to any chemical preparation in this
order that has been approved or denied as exempt. If any comments or
objections raise significant issues regarding any finding of fact or
conclusion of law upon which this order is based, the Assistant
Administrator will immediately suspend the effectiveness of any
applicable part of this order until he may reconsider the application
in light of the comments and objections filed.
Approved Exempt Chemical Preparations Are Posted on DEA's Web Site
A list of all current exemptions, including those listed in this
order, is available on the DEA's Web site at https://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf. The
dates of applications of all current exemptions are posted for easy
reference.
Dated: May 24, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-12110 Filed 6-9-17; 8:45 am]
BILLING CODE 4410-09-P